The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Top Cited Papers
Open Access
- 1 April 2016
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 29 (4), 574-586
- https://doi.org/10.1016/j.ccell.2016.03.008
Abstract
No abstract availableKeywords
Funding Information
- Damon Runyon Cancer Research Foundation
- Gabrielle's Angel Foundation for Cancer Research
This publication has 37 references indexed in Scilit:
- Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Molecular Cancer Therapeutics, 2015
- Role of Microenvironment in Resistance to Therapy in AMLCurrent Hematologic Malignancy Reports, 2015
- Recent advances of p53-MDM2 small molecule inhibitors (2011-present).Current Medicinal Chemistry, 2015
- The mutational landscapes of genetic and chemical models of Kras-driven lung cancerNature, 2014
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer ResearchCancer Discovery, 2014
- Lost in translation: animal models and clinical trials in cancer treatment.2014
- A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft ModelsCancer Research, 2013
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaBlood, 2012
- Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive BiomarkersClinical Cancer Research, 2008
- Phenotypic instability of Saos-2 cells in long-term cultureBiochemical and Biophysical Research Communications, 2005